Newsfeeds Archive - Page 34 of 56

2 minute read

Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials

February 16, 2:11 PM

Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd.

BWVI

2 minute read

Canada’s Ongoing Struggle For Access To Natural Psilocybin As A Therapeutic Nabs Business Support

By Lara Goldstein

February 15, 4:38 PM

Ontario-based Red Light Holland Corp. (OTCQB: TRUFF) has committed to becoming an aligned supporter and advocate with the non-profit TheraPsil.

TRUFF

2 minute read

Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US

By Lara Goldstein

February 15, 1:47 PM

Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications with the United S

CMND

2 minute read

Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial

By Lara Goldstein

February 15, 1:30 PM

Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.

DMTTF

2 minute read

Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program

By Lara Goldstein

February 14, 3:25 PM

Awakn Opens Fourth European Clinic, Norway Takes Center Stage

AWKNF

2 minute read

Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment

By Lara Goldstein

February 14, 2:58 PM

Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022. The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15 million as of Feb. 14, 2023.

CYBN

2 minute read

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder

By Lara Goldstein

February 14, 2:37 PM

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder.

KONEF

2 minute read

How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out

By Lara Goldstein

February 9, 6:19 PM

Licensed psychedelic drugs producer Optimi Health Corp. (OTCQX: OPTHF) submitted a Health Canada clinical trial application (CTA) for a Phase 1 study that will assess the safety of combining its natural psilocybin standardized extract with its proprietary MDMA drug candidate in healthy therapists.

OPTHF

1 minute read

A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability

By Lara Goldstein

February 9, 5:56 PM

Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral,

AWKNF